Sirnaomics Ltd (HKG: 2257) has announced the completion of the Phase I second sequence for its drug candidate STP122G, which is being developed as an anticoagulation treatment, along with the release of interim data. The Factor XI program, to which STP122G belongs, has broad therapeutic potential as an anticoagulant across a range of disease indications. It is being explored for the prevention and treatment of stroke in patients with atrial fibrillation, for cancer patients post-immunotherapy, and for improving recovery in total knee replacement surgeries, among other applications.
The Phase I study, which is single-center, randomized, double-blind, placebo-controlled, and involves sequence grouping, is designed to evaluate the safety, tolerability, and pharmacokinetics of STP122G in healthy subjects. The study aims to compare the safety and tolerability of STP122G across five dosages—25mg, 50mg, 100mg, 200mg, and 400mg—to establish the optimal dosage for subsequent trials. The second sequence of the trial included 8 healthy subjects who received a 50-milligram subcutaneous injection of STP122G and were followed up for 140 days. The safety data indicated that there were no dose-limiting toxicities or serious adverse events, and a dose-related target silencing activity was observed.- Flcube.com
